Revolutionizing Cancer Treatment: Plectonic Biotech Secures $500,000 in Pre-Seed Funding for Innovative LOGIBODY Immunotherapy Technology

Plectonic Biotech is excited to announce the successful raising of $500,000 in funding dedicated to advancing our innovative antibody-based immunotherapy technologies. Recognizing the immense potential of immunotherapies to treat tumor diseases, our team has focused on addressing a critical challenge in the field: the risk of unwanted over-stimulation of the immune system. This over-stimulation is primarily triggered by two factors: the presence of target antigens on both tumor and healthy tissues, and the global activity of antibodies throughout the body rather than being localized to the tumor. To combat this issue, we have pioneered a breakthrough solution—a groundbreaking ultra-miniaturized "on/off button" dubbed LOGIBODY. This DNA-based nanoswitch is meticulously designed to selectively recognize tumor cells, allowing for the precise recruitment of the body’s immune system to target and destroy cancerous cells while significantly reducing the impact on healthy tissues. Thus, minimizing side effects and enhancing the efficacy of treatment. The funding we have secured will enable us to further our research and development efforts, bringing us closer to clinical trials and ultimately transforming the way tumor diseases are treated through our innovative approach. We are thrilled about this next phase of growth and are committed to pioneering a future where patients receive safer, more effective immunotherapy options. Thank you to our supporters as we continue our journey in revolutionizing cancer treatment with targeted, logic-gated therapies!